Examples include the tumor suppressor BAP1, where nonsynonymous somatic mutations were associated with increased survival across the entire cohort (P = 0.018)–an effect driven primarily by the association of BAP1 mutations with survival benefit in HBV RNA negative patients (P = 0.008), as the vast majority of BAP1 mutations in the cohort (20 of 21) were found in HBV RNA negative tumors. Here, BAP1 is linked to neoplasm.